37. The porcine cell of claim 36, wherein the antigen is LFA-3.

38. The porcine cell of claim 36, wherein the antigen is ICAM-1.

39. The porcine cell of claim 36, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

40. The porcine cell of claim 36, wherein the antigen is masked with at least one masking agent.

41. The porcine cell of claim 40, wherein the antigen is masked with at least two masking agents.

42. The porcine cell of claim 41, wherein the at least two masking agents are obtained from polyclonal antisera raised against the antigen.

43. The porcine cell of claim 36, wherein the cell has at least two different antigens which are masked with at least two different masking agents.

44. The porcine cell of claim 36, wherein expression of the antigen on the cell is inhibited.

45. The porcine cell of claim 36, wherein the cell is harvested from a transgenic animal which has a diminished capacity to express the antigen on the surface of the cell.

46. The porcine cell of claim 36, wherein the cell comprises a genetically

engineered cell with increased capacity to express a cellular component.

47. The porcine cell of claim 40, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

48. The porcine cell of claim 44, wherein the masking agent is a non-lytic anti-MHC class I antibody or fragment thereof or an anti-MHC class II antibody or fragment thereof.

49. The porcine cell of claim 48, wherein the anti-MHC class I antibody fragment is an anti-MHC class I $F(ab')_2$ fragment.

50. The porcine cell of claim 36, which is a pancreatic islet cell.

51. The porcine cell of claim 36, which is a kidney cell.

52. The porcine cell of claim 36, which is a heart cell.

53. The porcine cell of claim 36, which is a muscle cell.

54. The porcine cell of claim 36, which is a liver cell.

55. The porcine cell of claim 36, which is a lung cell.

56. The porcine cell of claim 36, which is an endothelial cell.

57. The porcine cell of claim 36, which is a neuronal cell.

58. The porcine cell of claim 36, which is a parenchymal cell from a tissue or organ.

59. A non-lymphocytic porcine cell bearing a surface antigen capable of causing an immune response against the cell in a human recipient, wherein the antigen is masked to inhibit antigen-mediated rejection of the cell in the recipient.

60. A composition comprising a porcine cell and at least one masking agent, wherein the masking agent binds to a surface antigen of the porcine cell which is capable of causing an immune response against the cell in a human recipient.

61. A method for inhibiting rejection by a human recipient of porcine cells having a surface antigen which is capable of causing an immune response against the cells in the recipient, said method comprising modifying, masking, or partially or wholly eliminating the antigen to inhibit antigen-mediated rejection of the cells in the recipient.

62. The method of claim 61, wherein the antigen is LFA-3

63. The method of claim 61, wherein the antigen is ICAM-1.

64. The method of claim 61, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

65. The method of claim 61, wherein expression of the antigen on the cells is

inhibited.

66. The method of claim 61, wherein the cells are harvested from a transgenic animal which has diminished capacity to express the antigen on the surface of the cells.

67. The method of claim 61, wherein the cells comprise genetically engineered cells with increased capacity to express a cellular component.

68. The method of claim 61, wherein the antigen is masked with at least one masking agent.

69. The method of claim 68, wherein the antigen is masked with at least two masking agent.

70. The method of claim 61, wherein the cells have at least two different antigens which are masked with at least two different masking agents.

71. The method of claim 70, wherein the at least two masking agents are obtained from polyclonal antisera raised against the antigen.

72. The method of claim 68, wherein the antigen is an MHC class I antigen or an MHC class II antigen.

73. The method of claim 72, wherein the masking agent is an anti-MHC class I antibody or fragment thereof or an anti-MHC class II antibody or fragment thereof.

74. The method of claim 73, wherein the anti-MHC class I antibody fragment is an anti-MHC class I $F(ab')_2$ fragment.

75. The method of claim 61, wherein the cells are pancreatic islet cells.

76. The method of claim 61, wherein the cells are kidney cells.

77. The method of claim 61, wherein the cells are heart cells.

78. The method of claim 61, wherein the cells are muscle cells.

79. The method of claim 61, wherein the cells are liver cells.

80. The method of claim 61, wherein the cells are lung cells.

81. The method of claim 61, wherein the cells are endothelial cells.

82. The method of claim 61, wherein the cells are neuronal cells.

83. The method of claim 61, wherein the cells are parenchymal cells from a tissue or organ.